Ibrexafungerp (citrate)
Ibrexafungerp citrate (MK 3118 citrate) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections[1].
Product Specifications
CAS Number
[1965291-08-0]
Product Name Alternative
MK 3118 (citrate) ; SCY-078 (citrate)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Fungal
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/ibrexafungerp-citrate.html
Purity
99.38
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
Molecular Formula
C50H75N5O11
Molecular Weight
922.16
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-107126A/Ibrexafungerp-citrate-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-107126A/Ibrexafungerp-citrate-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items